Alzamend Neuro, Inc.
ALZN
$0.6525
-$0.0275-4.04%
NASDAQ
| 01/31/2025 | 10/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -43.62% | 38.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.61% | 41.12% | |||
| Operating Income | 23.61% | -41.12% | |||
| Income Before Tax | 23.66% | -39.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 23.66% | -39.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.66% | -39.74% | |||
| EBIT | 23.61% | -41.12% | |||
| EBITDA | 23.84% | -41.67% | |||
| EPS Basic | 52.98% | 68.01% | |||
| Normalized Basic EPS | 51.16% | 69.22% | |||
| EPS Diluted | 52.98% | 68.01% | |||
| Normalized Diluted EPS | 51.16% | 69.22% | |||
| Average Basic Shares Outstanding | 56.24% | 354.06% | |||
| Average Diluted Shares Outstanding | 56.24% | 354.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||